Navigation Links
Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
Date:8/5/2010

allows for the specific binding and selective uptake of the cytotoxic conjugate by LHRH-receptor-positive tumors. The binding of AEZS-108 to cancerous cells that express these receptors results in its accumulation and preferential uptake in the malignant tissue. AEZS-108 has already been studied in gynecologic cancers and has been shown to be effective and well tolerated in endometrial and ovarian cancer. Preclinical studies in animal models with prostate cancer also have demonstrated positive results with the drug.

AEZS-108 is currently in a Phase 2 trial conducted in Europe by the German AGO Study Group (Study AGO-GYN5), in advanced ovarian and endometrial cancer. Positive final Phase 2 results for ovarian cancer were disclosed in June 2010 at the annual American Society of Clinical Oncology ("ASCO") meeting, while those for endometrial cancer are expected by year-end. AEZS-108 has been granted orphan-drug designation by the FDA and has received a positive opinion for Orphan Medicinal Product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for the treatment of ovarian cancer.

About Prostate Cancer

According to the National Cancer Institute (NCI), prostate cancer is the second most prevalent type of cancer after lung cancer. The NCI estimates that 217,730 men will be diagnosed with and 32,050 men will die of prostate cancer in 2010 in the United States alone.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
2. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
3. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
4. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
5. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
9. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
10. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
11. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 According to a ... Cell Culture: Asia to Witness ... the global 3D cell culture market was valued at US$ 586.1 ... a CAGR of 29.1% to account for US$ 2,717.6 ... TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp 3D cell culture refers ...
(Date:7/31/2015)... 31, 2015 In today,s fast changing ... them drive positive health outcomes, improve profitability and ... patient care in their communities. At ThoughtSpot 2015, ... conference, AmerisourceBergen announced a new set of innovative ... Organization and help independent pharmacies endure the industry,s ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... and quantification of partially hydrolyzed gluten in foods, has been accepted by AOAC ... method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace ... for the interpretation and analysis of genomic and ... Fischer has joined the company as Vice ... - http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace ... to integrate, interpret, analyze and explore complex sets ...
Breaking Biology Technology:Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2
... have demonstrated that nanoparticles of cerium oxide -- common diesel ... engines -- can travel from the lungs to the liver ... The data in the study by Dr. Eric R. ... indicate there is a dose-dependent increase in the concentration of ...
... 17, 2011 Funds Will be ... Diagnostics System Designed to Drive the Widespread Adoption ... the Fight Against Infectious Disease Biocartis, ... (MDx) systems designed to drive the widespread adoption ...
... 17, 2011 SeraCare Life Sciences, Inc. (NASDAQ: ... vital products and services to facilitate the discovery, development ... financial results for its 2011 fiscal fourth quarter and ... "During the fourth quarter, we drove an ...
Cached Biology Technology:Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver 2Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising 2Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising 3Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising 4SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results 2SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results 3SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results 4SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results 5SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results 6
(Date:7/23/2015)... , July 23, 2015 Research and ... of the "Global Outlook of the Biometrics ... The global biometrics market is ... and commercial applications owing to the uptake of ... a transformation that enhances the growth of biometrics ...
(Date:7/21/2015)... 2015 Passwords have proven futile for ... recent U.S. Office of Personnel Management breach. Biometric ... conundrum, but developers and end-users are concerned about ... dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today the ... third party integration. A video ...
(Date:7/13/2015)... Conn. , Jul. 13, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/188684 for ... achieves another new convenient and secure method to ... new, innovative payment methods, introduced with its groundbreaking ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... by researchers at the European Centre for the Environment and ... Medicine and Dentistry) and the University of Birmingham has compared ... and concluded that the development of accurate simulations are likely ... because of infirmity or other limitations: but virtual worlds ...
... share about 95 percent of their genes, and mice ... model for studying human biology and disease. But, says ... even more "now that we really know what a ... Fernando Pardo-Manuel de Villena, Ph.D., of the University of ...
... or cod caught in the North Sea but declared as ... of fraud in the fisheries sector. A European Commission report ... genomics, chemistry and forensics - can provide clear answers to ... from.where was this fish caught.is it wild or farmed?". The ...
Cached Biology News:Virtual natural environments and benefits to health 2Virtual natural environments and benefits to health 3Virtual natural environments and benefits to health 4What is a laboratory mouse? Jackson, UNC researchers reveal the details 2What is a laboratory mouse? Jackson, UNC researchers reveal the details 3What fish is on your plate? 2
Use the DUALmembrane kit 3 to carry out DUALmembrane interaction analysis and cDNA library screening to characterize interactions between integral membrane proteins and to identify novel interaction ...
... Waterproof, moisture-proof film prevents sample evaporation, ... folded repeatedly and twisted around sharp ... 21C (70F), wrapping film increases approximately ... film only partially returns to original ...
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
...
Biology Products: